Home / Pharma news / Fosun Pharma complements the injectables platform created by Gland Pharma

Fosun Pharma complements the injectables platform created by Gland Pharma

Gland Pharma looked for many partners with the help of private equity partner KKR, but Shanghai’s Fosun Pharma came across as the best fit due to its global presence and size, said Vice Chairman and Managing Director Ravi Penmetsa in an interview to CNBC-TV18 after the Chinese conglomerate announced it will buy 86.1 percent stake in Gland for up to USD 1.26 billion. Penmetsa said Fosun complements the injectables platform created by Gland and provides scope to expand into front-end marketing. Fosun also has biosimilar and biological portfolio which can be brought into the injectables platform that Gland has, he added. Gland will now apply to the government and Penmetsa expects the deal could be completed in a few months. He does not see any regulatory hurdles as the deal fits well with the “Make in India” theme. Sharing his take on the deal, Sanjay Nayar, CEO of KKR India said it is good to see that capital invested by the fund helped Gland Pharma expand its facilities. He refrained from making any specific comments on the valuation of the deal but said valuations in the pharmaceutical space are calming down.

Read more at: http://www.moneycontrol.com/news/business/fosun-pharma-best-fit-due-to-global-presence-size-gland-pharma_7139461.html?utm_source=ref_article

apintus Labs is a global Pharmaceutical enterprise, offers  Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates (PIs) to clients based in various parts of the world.

http://apintuslabs.com/index.php?route=common/home

Check Also

Diabetes-Silent Killer

The total estimated cost of diagnosed diabetes in 2017 was $327 billion, including $237 billion ...

%d bloggers like this: